Aminophylline in 2026: A Provider Briefing

Aminophylline — the ethylenediamine salt of Theophylline — has been a fixture in respiratory medicine for decades. In 2026, however, prescribers face a significantly altered landscape: oral formulations have been permanently discontinued in the United States, and the IV formulation experiences intermittent supply disruptions. This article provides a concise overview of the current situation, prescribing implications, and available resources.

Timeline: How We Got Here

Understanding the timeline helps contextualize current challenges:

• 1950s-1990s: Aminophylline and Theophylline were mainstays of asthma and COPD management, widely prescribed in oral and IV forms.
• 1990s-2000s: Inhaled beta-2 agonists and inhaled corticosteroids emerged as preferred therapies. National and international guidelines (NAEPP, GINA, GOLD) progressively downgraded methylxanthines to third-line status.
• 2010s: Declining prescribing volumes made oral Aminophylline commercially unviable. Brand-name products like Phyllocontin and Truphylline were discontinued.
• 2020s: Oral Aminophylline tablets (100 mg, 200 mg) and oral solution are no longer manufactured in the US. The IV formulation (25 mg/mL) remains available through a limited number of generic manufacturers but faces periodic shortages consistent with broader trends in the sterile injectable market.

Prescribing Implications

Oral Therapy: Transition to Theophylline ER

For patients requiring ongoing oral methylxanthine therapy, Theophylline extended-release (Theo-24, Theochron) is the direct therapeutic equivalent. Key considerations for transition:

• Dose conversion: Aminophylline is approximately 79% Theophylline by weight. A patient on 200 mg oral Aminophylline was receiving ~158 mg of Theophylline.
• Therapeutic drug monitoring: Continue targeting serum Theophylline levels of 10-20 mcg/mL (some guidelines now suggest 5-15 mcg/mL for anti-inflammatory effects in COPD).
• Drug interactions: The CYP1A2-mediated metabolism of Theophylline remains a concern. Review for interactions with fluoroquinolones, macrolides, cimetidine, phenytoin, carbamazepine, and rifampin. Smoking status significantly affects clearance. See our comprehensive review of Aminophylline drug interactions.
• Special populations: Elderly patients, those with hepatic impairment or CHF, and patients with active infections require lower doses and more frequent monitoring.

IV Therapy: Managing Intermittent Availability

For acute settings where IV Aminophylline is indicated:

• Coordinate with your hospital pharmacy regarding current stock levels and anticipated supply timelines.
• Consider institutional protocols for IV Theophylline as an alternative (some institutions maintain both).
• For loading dose calculations in patients not currently on methylxanthines: 5.7-6 mg/kg Aminophylline IV over 20-30 minutes.
• Monitor serum levels within 30 minutes post-loading and adjust maintenance infusion accordingly (0.25-0.9 mg/kg/hr based on patient factors).

Current Availability Picture

Cost and Access Considerations

Understanding cost barriers helps ensure patient adherence:

• Theophylline ER: Generic pricing starts at approximately $26 for a 30-day supply with discount cards. Most insurance plans cover it as Tier 1/Tier 2 without prior authorization.
• Aminophylline IV: Hospital acquisition cost approximately $278-$400 per 500 mL bag. Covered under facility benefits.
• No manufacturer savings programs exist for Aminophylline — it's an older generic with no branded version on the market.
• Patient assistance: NeedyMeds and RxAssist can help uninsured or underinsured patients access Theophylline at reduced cost.

For patients reporting cost barriers, direct them to discount card resources or our patient-facing guide: How to save money on Aminophylline.

Tools and Resources for Providers

Medfinder for Providers offers real-time pharmacy stock data that can streamline the prescription-filling process for your patients. Key features:

• Real-time stock checking: Verify which local pharmacies have Theophylline ER or other alternatives in stock before you send the prescription.
• Patient referral: Direct patients to medfinder.com so they can independently verify availability.
• Shortage alerts: Stay informed about supply disruptions affecting your patients' medications.

Additional provider resources:

• FDA Drug Shortages Database: accessdata.fda.gov/scripts/drugshortages
• ASHP Drug Shortage Resource Center: ashp.org/drug-shortages
• For patient-facing guidance: Aminophylline shortage update for patients

Alternative Therapies to Consider

When transitioning patients off Aminophylline, the choice of alternative depends on the clinical scenario:

For Asthma

• Theophylline ER — Direct substitute; same mechanism
• Montelukast (Singulair) — Leukotriene receptor antagonist; useful as add-on therapy (note: boxed warning for neuropsychiatric effects)
• Long-acting beta-agonists (LABAs) — Salmeterol, Formoterol; always in combination with ICS per guidelines
• Biologics — Dupixent, Nucala, Xolair for severe, uncontrolled asthma

For COPD

• Theophylline ER — Third-line add-on per GOLD guidelines
• Tiotropium (Spiriva) — First-line LAMA; excellent bronchodilation
• Triple-combination inhalers — Trelegy Ellipta, Breztri Aerosphere (ICS/LABA/LAMA)
• Roflumilast (Daliresp) — PDE4 inhibitor for frequent exacerbators

For detailed alternative comparisons, see our article on alternatives to Aminophylline. For a provider-focused workflow guide, see how to help patients find Aminophylline in stock.

Looking Ahead

The outlook for oral Aminophylline returning to the US market is unlikely given current prescribing trends and guidelines. Methylxanthine use will continue to decline as newer targeted therapies gain traction, particularly biologics for severe asthma and combination inhalers for COPD.

However, Theophylline — including its IV form Aminophylline — still has a role in specific clinical scenarios: patients who fail inhaled therapies, acute severe asthma in the ED, neonatal apnea, and as an affordable option in resource-limited settings. Maintaining institutional protocols and familiarity with methylxanthine pharmacology remains relevant.

Final Thoughts

The Aminophylline supply situation in 2026 is one of permanent loss (oral) and intermittent challenge (IV). Proactive management — including patient education, formulary awareness, and use of tools like Medfinder for Providers — can minimize disruption to patient care. When transitions are needed, Theophylline ER remains the most seamless option, with Dyphylline and modern inhaled therapies providing additional flexibility.